Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Medically reviewed by Femi Aremu, PharmD Ozempic and Wegovy are both glucagon-like peptide-1 (GLP-1) receptor agonists and ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Semaglutide may be prescribed for different reasons and some forms may be more suitable for you than others: Ozempic. Ozempic is approved by the FDA (U.S. Food and Drug Administration) for type 2 ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance ...